Skip to main content

SYSTEMATIC REVIEW article

Front. Cardiovasc. Med.
Sec. Cardiovascular Pharmacology and Drug Discovery
Volume 11 - 2024 | doi: 10.3389/fcvm.2024.1477487

Efficacy and Safety of Cardiac Myosin Inhibitors for Symptomatic Hypertrophic Cardiomyopathy: A Meta-analysis of Randomized Controlled Trials

Provisionally accepted
Anas Abunada Anas Abunada 1Madiha shah Madiha shah 1Ateesh Kumar Ateesh Kumar 2Syeda Lamiya Mir Syeda Lamiya Mir 2Dinesh Kumar Dinesh Kumar 1Saboor Ahmed Saboor Ahmed 2Muhammad Tanzeel Muhammad Tanzeel 3Vikash Kumar Vikash Kumar 4Aashish Meghjiani Aashish Meghjiani 2Muhammad Basit Ali Siddiqui Muhammad Basit Ali Siddiqui 2Govinda Khatri Govinda Khatri 2Aneesh Rai Aneesh Rai 2FNU Deepak FNU Deepak 3Aayush Chaulagain Aayush Chaulagain 5*
  • 1 Liaquat University of Medical & Health Sciences, Jamshoro, Sindh, Pakistan
  • 2 Dow Medical College, Dow University of Health Sciences, Karachi, Punjab, Pakistan
  • 3 shaheed mohtarma benazir bhutto medical college lyari, Karachi, Pakistan
  • 4 Jinnah Sindh Medical University, Karachi, Sindh, Pakistan
  • 5 Patan Academy of Health Sciences, Patan, Nepal

The final, formatted version of the article will be published soon.

    Introduction: Hypertrophic cardiomyopathy (HCM) is a common genetic heart disorder. It is characterized by left ventricular hypertrophy and impaired cardiac function, with forms categorized into obstructive (oHCM) and nonobstructive (nHCM). Traditional treatments address symptoms but not the underlying disease mechanism, highlighting the need for novel therapies. Cardiac myosin inhibitors such as mavacamten and aficamten present potential new treatment options.A meta-analysis of randomized controlled trials (RCTs) was conducted following PRISMA guidelines. Studies comparing cardiac myosin inhibitors with placebo were reviewed, and outcomes related to NYHA functional class, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), LVOT gradients, and left ventricular ejection fraction (LVEF) were analyzed.Results: Six RCTs involving 826 participants demonstrated that mavacamten and aficamten significantly improved NYHA functional class and KCCQ-CSS scores. The incidence of treatmentemergent adverse events (TEAEs) and serious adverse events (SAEs) was similar between the treatment and control groups, indicating a comparable safety profile.Cardiac myosin inhibitors are effective in improving cardiac function and reducing LVOT obstruction in HCM patients. They offer a promising alternative to current treatments, with a safety profile comparable to placebo. Further research is needed to confirm long-term benefits.

    Keywords: Hypertrophic Cardiomyopathy, cardiac myosin inhibitors, Mavacamten, Aficamten, Lvot obstruction

    Received: 07 Aug 2024; Accepted: 27 Dec 2024.

    Copyright: © 2024 Abunada, shah, Kumar, Lamiya Mir, Kumar, Ahmed, Tanzeel, Kumar, Meghjiani, Siddiqui, Khatri, Rai, Deepak and Chaulagain. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Aayush Chaulagain, Patan Academy of Health Sciences, Patan, Nepal

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.